Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ANTIINFLAMMATORY EFFECTS OF BERAPROST SODIUM, A STABLE ANALOG OF PGI(2), AND ITS MECHANISMS
Autore:
UENO Y; KOIKE H; ANNOH S; NISHIO S;
Indirizzi:
TORAY INDUSTRIES LTD,BASIC RES LABS,1111 TEBIRO KAMAKURA KANAGAWA 248JAPAN
Titolo Testata:
Prostaglandins
fascicolo: 4, volume: 53, anno: 1997,
pagine: 279 - 289
SICI:
0090-6980(1997)53:4<279:AEOBSA>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
VASCULAR ENDOTHELIAL-CELLS; PROSTACYCLIN ANALOG; CYCLIC-AMP; PERMEABILITY; INCREASE; TRK-100; PROSTAGLANDIN-I2; MONOLAYERS; METABOLISM; AGONISTS;
Keywords:
BERAPROST SODIUM; ANTIINFLAMMATORY EFFECT; PULMONARY THROMBOEMBOLISM; LUNG EDEMA AND VENTRICULAR HYPERTROPHY; 5-HT-INDUCED EDEMA; PROSTAGLANDIN E-1;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
26
Recensione:
Indirizzi per estratti:
Citazione:
Y. Ueno et al., "ANTIINFLAMMATORY EFFECTS OF BERAPROST SODIUM, A STABLE ANALOG OF PGI(2), AND ITS MECHANISMS", Prostaglandins, 53(4), 1997, pp. 279-289

Abstract

We examined whether beraprost sodium (beraprost), a stable analogue of PGI(2), has an anti-inflammatory effect on the permeability barrier through endothelial cells in vivo. The injection of collagen (5 mu g/head) plus epinephrine (0.6 mu g/head) showed time-dependently the increased Evans blue dye leakage of the lung in mice for 60 min. Beraprostsignificantly suppressed this leakage dose-dependently (control; 11.26 +/- 2.64 mu g/lung, beraprost 10 mu g/kg; 7.49 +/- 1.36 mu g/lung, 30 mu g/kg; 5.33 +/- 0.71 mu g/lung, 100 mu g/kg; 5.52 +/- 0.79 mu g/lung). Pulmonary thromboembolism-induced Evans blue dye leakage was alsoreduced significantly by aspirin (5 mg/kg), but PGE(1) (170 mu g/kg) showed a tendency to potentiate the edematogenic response. One week after the injection of same dosage of collagen plus epinephrine in mice,pulmonary thromboembolism showed the increase of wet-to-dry weight ratio of the lung (normal; 3.84 +/- 0.01, control; 3.96 +/- 0.04) and right ventricular hypertrophy (normal; 28.2 +/- 0.9%, control; 32.3 +/- 0.9%) compared to normal mice. Beraprost significantly suppressed lungedema and hypertrophy dose-dependently, and over 30 mu g/kg/day of beraprost, the effects were statistically significant (beraprost 30 mu g/kg/day; 3.85 +/- 0.02 and 27.8 +/- 1.4 %, 100 mu g/kg/day; 3.85 +/- 0.02 and 27.3 +/- 1.1%). Beraprost significantly reduced 5-hydroxytryptamine (5-HT; 17 nmol/paw)-induced rat paw edema dose-dependently (5-HTalone; 100%, beraprost 10(-13) mol/paw; 91.19 +/- 2.22%, 20(-12) mol/paw; 85.79 +/- 4.85%, 10(-11) mol/paw; 78.49 +/- 3.95 %). 5-HT-inducededema was also suppressed significantly by the co-injection of (-)-isoproterenol (10(-12) mol/paw), but PGE(1) (10(-11) mol/paw) significantly potentiated the edematogenic response. From these results, we propose that the anti-inflammatory effect of beraprost may be contributed,in part, to the permeability barrier through end othelial cells in vivo. (C) 1997 by Elsevier Science Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/10/20 alle ore 00:13:20